LM

Lauren Maslin

Senior Associate, Portfolio Strategy at Paragon Therapeutics

Cambridge, Massachusetts

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Senior Associate, Portfolio Strategy

    2024

2022 - 2024

  • Senior Associate

    2024 - 2024

  • Associate

    2022 - 2024

  • Senior Analyst

    2021 - 2022

    • Promoted from part-time analyst (November 2019-August 2021) • Leads scientific and investment diligence on biotech companies with a focus in the oncology and immuno-oncology space • Authors multiple investment and declination memos highlighting a holistic analysis of the prospective companies; including technical, regulatory, market, financial and intellectual property analysis • Entrusted to represent Catalio at board meetings for several portfolio companies

  • Regulatory Postdoctoral Fellow

    2021 - 2021

    •Assisted in the submission of Investigational New Drug (IND) applications for oncology-related clinical trials •Provided regulatory guidance to IND sponsors, clinical investigators and clinical staff for investigator initiated clinical trials •Reviewed clinical trial databases to assess clinical data quality and accuracy

  • PhD Candidate

    2016 - 2021

    • Developed a novel approach to investigate the systemic vs tumor effects of MEK inhibition • Investigating novel drug combinations to maximize the positive immunomodulatory effects of MEK inhibition in RAS driven tumors

  • Cancer Research Intern

    2015 - 2015

    • Investigated the collaborative role of mutations in JAK2 and ASXL1 loss in Myeloproliferative Disorders • Selected from a pool of over 800 applicants for GSK Summer Undergraduate Research Program • 1 of 3 interns named 2015 Rubin and Sarah Shaps scholar

  • Cancer Research Intern

    2014 - 2014

    • Investigated if the relapse-specific mutations in NT5CIB found in patients with acute lymphoblastic leukemia were leading to resistance to nucleoside analogue chemotherapies • Selected from a pool of over 1,000 applicants for the NYU Summer Undergraduate Research Program